A型肉毒毒素治疗神经系统疾病的研究进展

doi:10.3969/j.issn.1006-9771.2019.09.008

摘要/Abstract

摘要： A型肉毒毒素(BoNT/A)的研究在许多方面取得迅速进展。BoNT/A被用于神经系统疾病，如疼痛、痉挛、肌张力障碍、自主神经功能障碍等的治疗。BoNT/A在神经传递和蛋白质之间相互作用的药理特性和作用机制已经被阐明，并促进了基础科学的研究。

关键词: A型肉毒毒素, 神经系统疾病, 综述

Abstract: The studies of Botulinum toxin A (BoNT/A) are progressing in many fields. BoNT/A has been used in neurological disorders, such as pains, spasticity, dystonias and autonomic disorders, etc. The pharmacological interaction among BoNT/A, neuronal transport and protein has been explored, and promoted basic science studies.

Key words: Botulinum toxin A, neurological disorders, review

中图分类号:

R741

刘开鑫, 巩朝阳, 向高, 张海鸿. A型肉毒毒素治疗神经系统疾病的研究进展[J]. 《中国康复理论与实践》, 2019, 25(9): 1038-1042.

LIU Kai-xin, GONG Chao-yang, XIANG Gao, ZHANG Hai-hong. Advance of Botulinum Toxin A in Neurological Disorders (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2019, 25(9): 1038-1042.

参考文献

1 SmithT J, HillK K, RaphaelB H. Historical and current perspectives on Clostridium Botulinum diversity [J]. Res Microbiol, 2015, 166(4): 290-302.
2 RossettoO, PirazziniM, MontecuccoC. Botulinum neurotoxins: genetic, structural and mechanistic insights [J]. Nat Rev Microbiol, 2014, 12(8): 535-549.
3 MontecuccoC, RasottoM B. On Botulinum neurotoxin variability [J]. MBio, 2015, 6(1): e02131-14.
4 Carrillo-MarquezM A. Botulism [J]. Pediatr Rev, 2016, 37(5): 183-192.
5 CarruthersJ, BurgessC, DayD, et al. Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices [J]. Dermatol Surg, 2016, 42(5): 586-597.
6 HallettM, AlbaneseA, DresslerD, et al. Evidence-based review and assessment of Botulinum neurotoxin for the treatment of movement disorders [J]. Toxicon , 2013, 67: 94-114.
7 DresslerD. Clinical applications of Botulinum toxin [J]. Curr Opin Microbiol, 2012, 15(3): 325-336.
8 MasuyerG, ChaddockJ A, FosterK A, et al. Engineered Botulinum neurotoxins as new therapeutics [J]. Annu Rev Pharmacol Toxicol, 2014, 54: 27-51.
9 MasuyerG, DaviesJ R, MooreK, et al. Structural analysis of Clostridium Botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors [J]. Sci Rep, 2015, 5: 13397.
10 HuL, ZouY, ChangS J, et al. Effects of Botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial [J]. Plast Reconstr Surg, 2018, 141(3): 646-650.
11 ChancellorM B, FowlerC J, ApostolidisA, et al. Drug insight: biological effects of Botulinum toxin A in the lower urinary tract [J]. Nat Clin Pract Urol, 2008, 5(6): 319-328.
12 EsquenaziA, AlbaneseA, ChancellorM B, et al. Evidence-based review and assessment of Botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome [J]. Toxicon, 2013, 67: 115-128.
13 TangQ, ChenC, WangX, et al. Botulinum toxin A improves adipose tissue engraftment by promoting cell proliferation, adipogenesis and angiogenesis [J]. Int J Mol Med, 2017, 40(3): 713-720.
14 ChenF, KuziemkoG M, StevensR C. Biophysical characterization of the stability of the 150-kilodalton Botulinum toxin, the nontoxic component, and the 900-kilodalton Botulinum toxin complex species [J]. Infect Immun, 1998, 66(6): 2420-2425.
15 RummelA. The long journey of Botulinum neurotoxins into the synapse [J]. Toxicon, 2015, 107(Pt A): 9-24.
16 FrevertJ. Content of Botulinum neurotoxin in Botox(R)/Vistabel(R), Dysport(R)/Azzalure(R), and Xeomin(R)/Bocouture(R) [J]. Drugs R D, 2010, 10(2): 67-73.
17 杨明娜,苏俊辉,张小龙,等. 原发性与面瘫后面肌痉挛患者面部异常运动A型肉毒毒素的治疗效果对比研究[J]. 卒中与神经疾病, 2019, 26(01): 77-81.
18 ComellaC L, PullmanS L. Botulinum toxins in neurological disease [J]. Muscle Nerve, 2004, 29(5): 628-644.
19 Ramirez-CastanedaJ, JankovicJ. Long-term efficacy, safety, and side effect profile of Botulinum toxin in dystonia: a 20-year follow-up [J]. Toxicon , 2014, 90: 344-348.
20 SimpsonD M, HallettM, AshmanE J, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology [J]. Neurology, 2016, 86(19): 1818-1826.
21 TsuiJ K, EisenA, MakE, et al. A pilot study on the use of Botulinum toxin in spasmodic torticollis [J]. Can J Neurol Sci, 1985, 12(4): 314-316.
22 WheelerA, SmithH S. Botulinum toxins: mechanisms of action, antinociception and clinical applications [J]. Toxicology, 2013, 306: 124-146.
23 曹腾腾,叶蕾,郑海霞. 扳机点注射A型肉毒杆菌毒素联合活血通络胶囊治疗原发性三叉神经痛疗效及对血浆CGRP、SP、IL-6、IL-1β水平的影响[J]. 现代中西医结合杂志, 2018, 27(30): 3328-3331, 3335.
24 ArgoffC E. A focused review on the use of Botulinum toxins for neuropathic pain [J]. Clin J Pain, 2002, 18(6 Suppl): S177-S181.
25 BuonocoreM, DemartiniL, MandriniS, et al. Effect of Botulinum toxin on disabling neuropathic pain: a case presentation suggesting a new therapeutic strategy [J]. PM R, 2017, 9(2): 200-203.
26 MorraM E, ElgebalyA, ElmaraezyA, et al. Therapeutic efficacy and safety of Botulinum toxin A therapy in trigeminal neuralgia: a systematic review and meta-analysis of randomized controlled trials [J]. J Headache Pain, 2016, 17(1): 63.
27 杨琼,李剑,张洁,等. A型肉毒素治疗原发性头痛研究进展[J]. 中国神经免疫学和神经病学杂志, 2018, 25(6): 439-442.
28 ChenS. Clinical uses of Botulinum neurotoxins: current indications, limitations and future developments [J]. Toxins, 2012, 4(10): 913-939.
29 LuvisettoS, GazeraniP, CianchettiC, et al. Botulinum toxin type A as a therapeutic agent against headache and related disorders [J]. Toxins, 2015, 7(9): 3818-3844.
30 CutrerF M. Pathophysiology of migraine [J]. Semin Neurol, 2010, 30(2): 120-130.
31 OlesenJ, BursteinR, AshinaM, et al. Origin of pain in migraine: evidence for peripheral sensitisation [J]. Lancet Neurol, 2009, 8(7): 679-690.
32 ShevelE. The extracranial vascular theory of migraine－a great story confirmed by the facts [J]. Headache, 2011, 51(3): 409-417.
33 JacksonJ L, KuriyamaA, HayashinoY. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis [J]. JAMA, 2012, 307(16): 1736-1745.
34 刘景隆,郭天龙,吕英,等. A型肉毒素局部注射对脑卒中后痉挛性上肢功能障碍的影响[J]. 中国康复理论与实践, 2012, 18(7): 640-642.
35 DresslerD, SaberiF A, KolleweK, et al. Safety aspects of incobotulinumtoxinA high-dose therapy [J]. J Neural Transm (Vienna), 2015, 122(2): 327-333.
36 SantamatoA, MicelloM F, RanieriM, et al. Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke [J]. J Neurol Sci, 2015, 350(1-2): 1-6.
37 KutschenkoA, ManigA, ReinertM C, et al. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA [J]. Neurosci Lett, 2016, 627: 216-221.
38 GraciesJ M, LugassyM, WeiszD J, et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study [J]. Arch Phys Med Rehabil, 2009, 90(1): 9-16, e2.
39 AlbaneseA, LalliS. Is this dystonia? [J]. Mov Disord, 2009, 24(12): 1725-1731.
40 AlbaneseA, LalliS. Update on dystonia [J]. Curr Opin Neurol, 2012, 25(4): 483-490.
41 刘建军,纪树荣. A型肉毒毒素治疗痉挛的临床应用[J]. 中国康复理论与实践, 2001, 7(3): 39-40.
42 GraciesJ M. Physiological effects of botulinum toxin in spasticity [J]. Mov Disord, 2004, 19(Suppl 8): S120-S128.
43 GiladiN. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site [J]. J Neurol Sci, 1997, 152(2): 132-135.
44 HallettM. How does botulinum toxin work? [J]. Ann Neurol, 2000, 48(1): 7-8.
45 RosalesR L, DresslerD. On muscle spindles, dystonia and botulinum toxin [J]. Eur J Neurol, 2010, 17(Suppl 1): 71-80.
46 CaleoM, SchiavoG. Central effects of tetanus and botulinum neurotoxins [J]. Toxicon, 2009, 54(5): 593-599.
47 HubbardK, BeskeP, LymanM, et al. Functional evaluation of biological neurotoxins in networked cultures of stem cell-derived central nervous system neurons [J]. J Vis Exp, 2015. doi: 10.3791/52361.
48 BentivoglioA R, del GrandeA, PetraccaM, et al. Clinical differences between Botulinum neurotoxin type A and B [J]. Toxicon, 2015, 107(Pt A): 77-84.
49 KarpB I. Botulinum toxin treatment of occupational and focal hand dystonia [J]. Mov Disord, 2004, 19(Suppl 8): S116-S119.
50 SchneiderS A, EdwardsM J, CordivariC, et al. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease [J]. Mov Disord, 2006, 21(10): 1722-1724.
51 BentivoglioA R, FasanoA, IalongoT, et al. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm [J]. Eur J Neurol, 2009, 16(3): 392-398.
52 LotiaM, JankovicJ. Botulinum toxin for the treatment of tremor and tics [J]. Semin Neurol, 2016, 36(1): 54-63.
53 SimoensS, LaekemanG. Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach [J]. Allergy, 2009, 64(1): 85-95.
54 OzcanC, IsmiO. Botulinum toxin for rhinitis [J]. Curr Allergy Asthma Rep, 2016, 16(8): 58.
55 钟海虎. 逼尿肌内注射A型肉毒毒素对特发性膀胱过度活动症和神经源性膀胱过度活动症疗效的比较[J]. 中国医学创新, 2018, 15(16): 1-5.
56 SchurchB, StohrerM, KramerG, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results [J]. J Urol, 2000, 164(3 Pt 1): 692-697.
57 FowlerC J, GriffithsD, de GroatW C. The neural control of micturition [J]. Nat Rev Neurosci, 2008, 9(6): 453-466.
58 ApostolidisA, PopatR, YiangouY, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity [J]. J Urol, 2005, 174(3): 977-983.
59 DugganM J, QuinnC P, ChaddockJ A, et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin [J]. J Biol Chem, 2002, 277(38): 34846-34852.
60 RappD E, TurkK W, BalesG T, et al. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder [J]. J Urol, 2006, 175(3 Pt 1): 1138-1142.
61 KheraM, SomogyiG T, KissS, et al. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury [J]. Neurochem Int, 2004, 45(7): 987-993.
62 ChuangY C, YoshimuraN, HuangC C, et al. Intraprostatic Botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat [J]. J Urol, 2008, 180(2): 742-748.
63 SmithC P, RadziszewskiP, BorkowskiA, et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis [J]. Urology, 2004, 64(5): 871-875.
64 WangJ, WangQ, WuQ, et al. Intravesical Botulinum toxin A injections for bladder pain syndrome/interstitial cystitis: a systematic review and meta-analysis of controlled studies [J]. Med Sci Monit, 2016, 22: 3257-3267.
65 LiuB L, YangF, ZhanH L, et al. Increased severity of inflammation correlates with elevated expression of TRPV1 nerve fibers and nerve growth factor on interstitial cystitis/bladder pain syndrome [J]. Urol Int, 2014, 92(2): 202-208.
66 PapagiannopoulouD, VardouliL, DimitriadisF, et al. Retrograde transport of radiolabelled Botulinum neurotoxin type A to the CNS after intradetrusor injection in rats [J]. BJU Int, 2016, 117(4): 697-704.

[1]	邵伟婷, 雷江华. 反应中断再定向干预孤独症谱系障碍儿童刻板语言的效果：Scoping综述[J]. 《中国康复理论与实践》, 2024, 30(1): 10-20.
[2]	王航宇, 葛可可, 范永红, 都丽露, 邹敏, 封磊. 基于ICD-11和ICF主动式音乐疗法改善认知障碍老年人认知功能的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 36-43.
[3]	闻嘉宁, 金秋艳, 张琦, 李杰, 司琦. 认知参与型身体活动对发展儿童青少年执行功能的效果：基于ICF的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 44-53.
[4]	葛可可, 范永红, 王航宇, 都丽露, 李长江, 邹敏. 失眠老年人正念干预健康效益的系统综述[J]. 《中国康复理论与实践》, 2024, 30(1): 54-60.
[5]	张婧雅, 邹敏, 孙宏伟, 孙昌隆, 朱峻同. 听障儿童青少年焦虑或抑郁情绪心理干预效果的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1004-1011.
[6]	王俊宇, 杨永, 袁逊, 谢婷, 庄洁. 高强度间歇训练对健康儿童青少年执行功能效果的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1012-1020.
[7]	魏晓微, 杨剑, 魏春艳. 特殊教育学校孤独症谱系障碍儿童参与适应性瑜伽活动的心理与行为效益的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1021-1028.
[8]	杨亚茹, 杨剑. 基于WHO-HPS架构学校身体活动相关健康服务及其健康效益：系统综述的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1040-1047.
[9]	史佳伟, 李凌宇, 杨浩杰, 王琴潞, 邹海欧. 预康复对全膝关节置换术后患者的有效性：系统综述的系统综述[J]. 《中国康复理论与实践》, 2023, 29(9): 1057-1064.
[10]	蒋长好, 黄辰, 高晓妍, 戴元富, 赵国明. 神经反馈训练对老年人认知功能效果的系统综述[J]. 《中国康复理论与实践》, 2023, 29(8): 903-909.
[11]	魏晓微, 杨剑, 魏春艳, 贺启令. 学校环境下适应性体育课程促进智力与发展性残疾儿童心理运动发展的系统综述[J]. 《中国康复理论与实践》, 2023, 29(8): 910-918.
[12]	张园, 杨剑. 基于世界卫生组织健康促进学校架构的学校健康服务及效果：Scoping综述[J]. 《中国康复理论与实践》, 2023, 29(7): 791-799.
[13]	王少璞, 陈钢. 基于世界卫生组织健康促进学校架构的心理行为健康服务及其健康效益：系统综述的系统综述[J]. 《中国康复理论与实践》, 2023, 29(7): 800-807.
[14]	蒋长好, 高晓妍. 短时身体活动对儿童认知功能影响的系统综述[J]. 《中国康复理论与实践》, 2023, 29(6): 667-672.
[15]	袁媛, 杨剑. 社区老年人身体活动融合慢性病管理的健康效益：Scoping综述[J]. 《中国康复理论与实践》, 2023, 29(5): 541-550.